{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug%3A+Atrasentan",
    "query": {
      "intervention": "Drug: Atrasentan"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T13:17:36.483Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00271492",
      "title": "Correlation of Endothelial Function and Early Coronary Artery Disease in Humans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endothelial Dysfunction"
      ],
      "interventions": [
        {
          "name": "atrasentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 200,
      "start_date": "2001-07",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2010-04-30",
      "last_synced_at": "2026-09-28T13:17:36.483Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00271492"
    },
    {
      "nct_id": "NCT07498335",
      "title": "Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Berger Disease",
        "Bergers Disease",
        "IgA Nephropathy",
        "Immunoglobulin A Nephropathy",
        "Primary IgAN",
        "Nephritis IgA Type, Nephropathy IgA Type"
      ],
      "interventions": [
        {
          "name": "Drug: Atrasentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 28,
      "start_date": "2026-08-06",
      "completion_date": "2032-12-13",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-09-28T13:17:36.483Z",
      "location_count": 4,
      "location_summary": "Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07498335"
    },
    {
      "nct_id": "NCT00920764",
      "title": "A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Placebo for Atrasentan 0.2 mg/mL solution",
          "type": "DRUG"
        },
        {
          "name": "0.25 mg Atrasentan QD",
          "type": "DRUG"
        },
        {
          "name": "0.75 mg Atrasentan QD",
          "type": "DRUG"
        },
        {
          "name": "1.75 mg Atrasentan QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2009-06",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-09-28T13:17:36.483Z",
      "location_count": 24,
      "location_summary": "Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920764"
    }
  ]
}